IP Verse

Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile

Patent No. EP3070090 (titled "Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile") was filed by Incyte on Jun 12, 2008. The application was issued on Dec 12, 2018.

Patent Summary

Salt forms of a JAK inhibitor drug called (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile for treating polycythemia vera. The salt forms include maleic, sulfuric, and phosphoric acid salts. These salt forms provide improved solubility and bioavailability compared to the free base form. Administering the salt forms in combination with corticosteroids like dexamethasone can improve efficacy for treating diseases associated with JAK expression or activity.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKSep 6, 2019HGF

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3070090

INCYTE
Application Number
EP16152794A
Filing Date
Jun 12, 2008
Status
Revoked
Nov 26, 2021
Publication Date
Dec 12, 2018
External Links
Slate, Register , Google Patents